Spring til indhold.

Portrait

Kenneth Kastaniegaard

Kenneth Kastaniegaard

PhD thesis title and year of degree: Biochemical model for the development of neurodegenerative diseases – The role of posttranslational modifications of proteins, extracellular vesicles and autoimmune development - 2019.

Portrait

Kenneth Kastaniegaard

Kenneth Kastaniegaard

PhD thesis title and year of degree: Biochemical model for the development of neurodegenerative diseases – The role of posttranslational modifications of proteins, extracellular vesicles and autoimmune development - 2019.

Career path in short

I co-founded Biogenity in May 2018 while completing my PhD. Since then, it has grown into a successful global contract research organization specializing in Proteomics, Transcriptomics, and Metabolomics.

In addition to commercial success, we actively contribute to the scientific community through participation in two major EU-funded research projects: EXIMIOUS and EXPOSIM.

In June 2024, I co-founded my second venture, Omics Studio, where we are developing software to help researchers analyze and contextualize omics data—specifically in Proteomics, Transcriptomics, and Metabolomics.

The company has already secured pre-seed investment, received soft funding, and entered the market by serving its first customers.

What do you use from your PhD education/training?

With a background in omics, along with strong coding abilities and project management experience.

Did you miss something during your PhD?

Expectation management.

Do you find that a PhD degree is a good starting point for a career outside academia?

Indeed, the required knowledge and skills were critical to success.

Facts about Kenneth Kastaniegaard

  • Education: Medical Bioteknology
  • Current position/company: CEO – Biogenity & Omics Studio
  • LinkedIn profile

View more portraits